Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Neoadjuvant Chemotherapy (FAP) for Advanced Esophageal Cancer

TAKESHI SHIMAKAWA, YOSHIHIKO NARITAKA, SHINICHI ASAKA, NORIYUKI ISOHATA, MINORU MURAYAMA, SOICHI KONNO, KAZUHIKO YOSHIMATSU, SHUNICHI SHIOZAWA, TAKAO KATSUBE and KENJI OGAWA
Anticancer Research July 2008, 28 (4C) 2321-2326;
TAKESHI SHIMAKAWA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHIHIKO NARITAKA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHINICHI ASAKA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NORIYUKI ISOHATA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MINORU MURAYAMA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SOICHI KONNO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUHIKO YOSHIMATSU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHUNICHI SHIOZAWA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKAO KATSUBE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KENJI OGAWA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: simakasu@dnh.twmu.ac.jp
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

This study was performed to assess the usefulness and safety of neoadjuvant chemotherapy utilizing the FAP regimen consisting of 5-fluorouracil, cisplatin and adriamycin for the treatment of highly advanced esophageal cancer. Twenty-seven patients with Stage III or more advanced esophageal cancer were enrolled in the study. The patients generally received two cycles of FAP. The response rate was as high as 55.6% and the resectability rate as high as 85.2% . All adverse events reported were mild in intensity. The histological effect was assessed as follows: Grade 1 in 18 patients, Grade 2 in 3 patients and Grade 3 (a pathological complete response) in 2 patients. All patients with nonresectable tumors died within 6 months, whereas of the 5 patients who responded with Grade 2 or better histological effects, all survived without recurrence for a follow-up period up to 60 months. The results of this study therefore showed the usefulness and safety of FAP therapy, which is considered to be a treatment method worth aggressively trying for highly advanced esophageal cancer in which a curative resection can hardly be expected.

  • Esophageal cancer
  • neoadjuvant chemotherapy
  • FAP

Footnotes

  • Received December 21, 2007.
  • Revision received March 7, 2008.
  • Accepted March 17, 2008.
  • Copyright© 2008 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 28 (4C)
Anticancer Research
Vol. 28, Issue 4C
July-August 2008
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Neoadjuvant Chemotherapy (FAP) for Advanced Esophageal Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
5 + 7 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Neoadjuvant Chemotherapy (FAP) for Advanced Esophageal Cancer
TAKESHI SHIMAKAWA, YOSHIHIKO NARITAKA, SHINICHI ASAKA, NORIYUKI ISOHATA, MINORU MURAYAMA, SOICHI KONNO, KAZUHIKO YOSHIMATSU, SHUNICHI SHIOZAWA, TAKAO KATSUBE, KENJI OGAWA
Anticancer Research Jul 2008, 28 (4C) 2321-2326;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Neoadjuvant Chemotherapy (FAP) for Advanced Esophageal Cancer
TAKESHI SHIMAKAWA, YOSHIHIKO NARITAKA, SHINICHI ASAKA, NORIYUKI ISOHATA, MINORU MURAYAMA, SOICHI KONNO, KAZUHIKO YOSHIMATSU, SHUNICHI SHIOZAWA, TAKAO KATSUBE, KENJI OGAWA
Anticancer Research Jul 2008, 28 (4C) 2321-2326;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • A Case of Esophageal Cancer with Multiple Lymph Node Metastases which Responded to Neoadjuvant Chemotherapy (DCF therapy)
  • Enhancement of Doxorubicin Cytotoxicity on Human Esophageal Squamous Cell Carcinoma Cells by Indomethacin and 4-[5-(4-Chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC236) via Inhibiting P-Glycoprotein Activity
  • Google Scholar

More in this TOC Section

  • Comparison of BRCA2 Single Nucleotide Variants Between Japanese Patients With Familial Prostate Cancer, Sporadic Prostate Cancer, and Benign Prostatic Hyperplasia
  • Corrigendum
  • Sex-related Survival Differences in Patients With Glioblastoma – Results From a Retrospective Analysis
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire